[8-K] ANEW MEDICAL, INC. Common Stock Reports Material Event

Rhea-AI Filing Summary

Form 8-K filing – Item 8.01 Other Events

On July 10 2025, Snap Inc. (NYSE: SNAP) filed a current report to notify investors that its 2025 annual meeting of stockholders is scheduled for August 1 2025. The full agenda and voting information are contained in the Information Statement filed as Exhibit 99.1. Shareholders of all classes, including Class A common stock, may attend virtually via investor.snap.com.

No financial results, strategic transactions, executive changes, or material business updates were disclosed. The only additional exhibit is an Inline XBRL cover-page data file (Exhibit 104), which is standard for SEC compliance.

Because the disclosure is limited to meeting logistics and contains no earnings or operational data, the filing is considered routine with minimal impact on Snap’s valuation or near-term outlook.

Insights

Corporate Governance Analyst

TL;DR: Routine 8-K sets Aug 1 2025 shareholder meeting; no financial or strategic content; neutral effect on SNAP shares.

The company’s sole purpose in this filing is to formally announce the 2025 annual meeting date and release the accompanying information statement. Such notices are required under SEC rules but do not, by themselves, alter governance structure, capital allocation, or earnings prospects. The absence of board or by-law changes, compensation adjustments, or contested proposals means investors should view the document as procedural. Unless the forthcoming proxy materials reveal controversial items, the market impact remains negligible.

false 0001907223 0001907223 2025-07-10 2025-07-10 0001907223 us-gaap:CommonStockMember 2025-07-10 2025-07-10 0001907223 KLTO:WarrantsMember 2025-07-10 2025-07-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): July 10, 2025

Klotho Neurosciences, Inc.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation)

001-41340		86-2727441
(Commission File Number)		(IRS Employer Identification No.)

13576 Walnut Street, Suite A
Omaha, NE 68144

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code (833) 931-6330

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol(s)		Name of Each Exchange on Which Registered
Common Stock		KLTO		The Nasdaq Stock Market LLC
Warrants		KLTOW		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On July 10, 2025, Klotho Neuroscience, Inc. (the “Company”) issued a press release regarding the U.S. Food and Drug Administration (the “FDA”) granting Orphan Drug Designation for the Company’s KLTO-202 for Treatment of Amyotrophic Lateral Sclerosis also know as “ALS” or “Lou Gehrig’s Disease.” A copy of the press release is attached hereto as Exhibit 99.1.

The information contained in this Item 7.01 and Exhibit 99.1, attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended and shall not be deemed incorporated by reference in any filing with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended or the Securities Act of 1933, as amended whether made before or after the date hereof and irrespective of any general incorporation language in any filings.

This Form 8-K contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company’s future commercial operations. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, such as the Company’s inability to implement its business plans, identify and realize additional opportunities, or meet or exceed its financial projections and changes in the regulatory or competitive environment in which the Company operates. You should carefully consider the foregoing factors and the other risks and uncertainties described in the documents filed or to be filed by the Company with the U.S. Securities and Exchange Commission (the “SEC”) from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements. Copies of these documents are available on the SEC’s website, www.sec.gov. All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.

Item 9.01 Financial Statements and Exhibits.

Exhibits		Description
99.1		Press Release
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: July 10, 2025	KLOTHO NEUROSCIENCES, INC.
	By:	/s/ Joseph Sinkule
	Name:	Joseph Sinkule
	Title:	Chief Executive Officer

2

FAQ

When will Snap Inc. (SNAP) hold its 2025 annual meeting of stockholders?

The meeting is scheduled for August 1 2025.

How can SNAP shareholders attend the 2025 annual meeting?

All shareholders can access the virtual meeting at investor.snap.com.

What information is provided in Exhibit 99.1 of Snap's Form 8-K?

Exhibit 99.1 contains the Information Statement detailing the meeting agenda and voting procedures.

Does this Form 8-K include any financial results or guidance from Snap Inc.?

No. The filing is limited to announcing the annual meeting and includes no earnings or guidance data.

Are there any major corporate actions disclosed under Item 8.01 in this filing?

No material corporate actions were disclosed; the filing is purely procedural.